Clinico-Epidemiological Profile Of Acquired Aplastic Anemia Among Children At Assiut Governorate .

NCT ID: NCT07259863

Last Updated: 2025-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

35 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-01

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Assessment the clinical presentation and epidemiological profile of children with acquired aplastic anemia.
2. Determining the possible risk factors and associated conditions contributing to the development of acquired aplastic anemia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aplastic anaemia is a term describing the common findings of pancytopenia and marrow hypoplasia from arising variety of disease states, including acquired aplastic anaemia and a variety of congenital marrow failure states(1). The global incidence of paediatric AA varies geographically, with rates of 2 to 3 cases per million per year in Europe, but higher in East Asia and certain developing regions(2) .Among Egyptian Children, inherited bone marrow failure syndromes (BMFS), including AA, constitute about 10-15%of all BMFS and up to 30% of paediatric BMFS ,with an average of 65 cases per million live births each year .Acquired AA remains the predominant from in older children and adolescent , while inherited forms are more common in younger children(3).The clinical presentation of aplastic anaemia regularly consists of symptoms associated with pancytopenia, including fatigue, pallor, bruising, bleeding, and extended susceptibility to infections(4). Identified etiologic risk factors include infections of viral origin, such as hepatitis-associated, Epstein-Barr, parvovirus, human immunodeficiency virus, varicella zoster, measles and other viruses, as well as exposure to toxic chemicals (e.g. benzene, pesticides and insecticides) and ionizing radiation (5). Over the last three decades, bone marrow transplantation (BMT) from a matched related donor (MRD) has been the treatment of choice for children with acquired AA (6) The Rationale of our study: aplastic anaemia in children is a serious ,life threatening bone marrow failure syndrome ,often resulting from immune-mediated destruction of hematopoietic stem cell triggered by factors such as viral infections, environmental toxin, or genetic predispositions and requires precise diagnosis to distinguish from inherited bone marrow failure syndromes or hypoplastic myelodysplastic syndrome to guide appropriate treatment strategies .

The Research question: What is the clinico-epidemiological profile of acquired aplastic anaemia among children at Assiut governorate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acquired Aplastic Anaemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

observational case series study no intervention

Assessment the clinical presentation and epidemiological profile of children with acquired aplastic anemia. 2.Determining the possible risk factors and associated conditions contributing to the development of acquired aplastic anemia.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1- Children aged 1-18 years old diagnosed with acquired aplastic anemia 2-Fulfillment of the diagnostic criteria for acquired AA 3-patient with complete medical records,including diagnostic ,labaratory and treatement data 4-Diagnosed or treated at assuit university children hospital and the central health insurance clinic at assuit Governorate (october 2020 to october 2026)

Exclusion Criteria

* 1-children with congental bone marrow failure syndrome 2-patient with a history of chemotherapy or radiotherapy prior to diagnosis 2-cases with incomplete medical or insufficient medical records that prevented confirmination of diagnosis or extraction of essential study data
Minimum Eligible Age

1 Year

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sara Ramadan Hassanein Hassan

Assistant Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mostafa Mohamed Embaby, professor of pediatic

Role: PRINCIPAL_INVESTIGATOR

Departement of Familly medicine Assuit University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sara Ramadan Hassanein, Resident doctor

Role: CONTACT

+2001018426240

Hamdy Mohamed Mohamed, Lecturer at familly medicine

Role: CONTACT

+2001000882184

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Aplastic anemia in children .

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thrombophilia In Beta Thalassemia
NCT04219449 NOT_YET_RECRUITING